Policy Proposal and Financial Implications
The administration has proposed a rule to extend Medicare and coverage to obesity treatments like and Ozempic, potentially costing taxpayers up to $35 billion over the next decade.
The initiative aims to address the obesity epidemic, with the reporting over 40% of U.S. adults are obese, by making these drugs more accessible, potentially reducing out-of-pocket costs by up to 95% for some enrollees.
Political and Public Health Controversies
, nominated for HHS Secretary, opposes the coverage, advocating for investments in healthier foods and exercise instead, sparking a potential clash with pharmaceutical companies and health policy reform advocates.
Critics argue the proposal may overlook underlying health issues and lead to increased reliance on pharmaceuticals, while supporters believe it could significantly improve public health and reduce long-term medical costs related to obesity.